Application of transurethral blue laser vaporization of the prostate in Patients Aged 80 and Above: A Single-Center Clinical Analysis of 157 Cases

Purpose: This study aims to assess the safety and effectiveness of transurethral blue laser prostate vaporization (BVP) for elderly patients (≥80 years) with benign prostatic hyperplasia (BPH), focusing on clinical outcomes, recovery, and complications. Methods: A retrospective analysis was performed on 157 BPH patients aged ≥80 years who underwent BVP at a single center between May 2023 and May 2025. Data on demographics, prostate volume, comorbidities, procedure details, and postoperative outcomes were collected. Results: The mean age was 83.97±3.63 years, with an average prostate volume of 63.34±34.95 ml. Patients had an average of 2.5 comorbidities, and 26.1% required additional surgical interventions. The average procedure time was 28.2±12.1 minutes, with a median hospital stay of 9 days. Postoperative IPSS scores decreased significantly to 4.3±3.5. Mild red blood cell loss (hemoglobin decreased by 6.1%, p<0.001) and a significant inflammatory response (neutrophils increased by 26.5%, p<0.001) were observed, but no transfusion was needed. Conclusion: Transurethral blue laser prostate vaporization is a safe and effective option for elderly BPH patients with multiple comorbidities, offering significant symptom improvement with minimal postoperative complications.